1 Study Coverage 1.1 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Product Introduction 1.2 Market by Type 1.2.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 1.2.2 0.5ml Package 1.2.3 1ml Package 1.2.4 2ml Package 1.2.5 Other 1.3 Market by Application 1.3.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 1.3.2 0-5 Years Old 1.3.3 5-18 Years Old 1.3.4 18-45 Years Old 1.3.5 45-65 Years Old 1.3.6 ≥65 Years Old 1.4 Study Objectives 1.5 Years Considered 2 Executive Summary 2.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Estimates and Forecasts 2017-2028 2.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Estimates and Forecasts 2017-2028 2.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Region: 2017 VS 2021 VS 2028 2.4 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Region 2.4.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Region (2017-2022) 2.4.2 Global Sales VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 by Region (2023-2028) 2.5 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Region 2.5.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Region (2017-2022) 2.5.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Region (2023-2028) 2.6 North America 2.7 Europe 2.8 Asia-Pacific 2.9 Latin America 2.10 Middle East & Africa 3 Competition by Manufacturers 3.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Manufacturers 3.1.1 Global Top VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Manufacturers by Sales (2017-2022) 3.1.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Manufacturers (2017-2022) 3.1.3 Global Top 10 and Top 5 Largest Manufacturers of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 in 2021 3.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Manufacturers 3.2.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Manufacturers (2017-2022) 3.2.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Manufacturers (2017-2022) 3.2.3 Global Top 10 and Top 5 Companies by VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue in 2021 3.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Price by Manufacturers (2017-2022) 3.4 Analysis of Competitive Landscape 3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI) 3.4.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.4.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Manufacturers Geographical Distribution 3.5 Mergers & Acquisitions, Expansion Plans 4 Market Size by Type 4.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type 4.1.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Historical Sales by Type (2017-2022) 4.1.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Forecasted Sales by Type (2023-2028) 4.1.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Type (2017-2028) 4.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Type 4.2.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Historical Revenue by Type (2017-2022) 4.2.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Forecasted Revenue by Type (2023-2028) 4.2.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Type (2017-2028) 4.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Price by Type 4.3.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Price by Type (2017-2022) 4.3.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Price Forecast by Type (2023-2028) 5 Market Size by Application 5.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application 5.1.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Historical Sales by Application (2017-2022) 5.1.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Forecasted Sales by Application (2023-2028) 5.1.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Application (2017-2028) 5.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Application 5.2.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Historical Revenue by Application (2017-2022) 5.2.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Forecasted Revenue by Application (2023-2028) 5.2.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Application (2017-2028) 5.3 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Price by Application 5.3.1 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Price by Application (2017-2022) 5.3.2 Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Price Forecast by Application (2023-2028) 6 North America 6.1 North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Type 6.1.1 North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2017-2028) 6.1.2 North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Type (2017-2028) 6.2 North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Application 6.2.1 North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2017-2028) 6.2.2 North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Application (2017-2028) 6.3 North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Country 6.3.1 North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2017-2028) 6.3.2 North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2017-2028) 6.3.3 U.S. 6.3.4 Canada 7 Europe 7.1 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Type 7.1.1 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2017-2028) 7.1.2 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Type (2017-2028) 7.2 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Application 7.2.1 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2017-2028) 7.2.2 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Application (2017-2028) 7.3 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Country 7.3.1 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2017-2028) 7.3.2 Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2017-2028) 7.3.3 Germany 7.3.4 France 7.3.5 U.K. 7.3.6 Italy 7.3.7 Russia 8 Asia Pacific 8.1 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Type 8.1.1 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2017-2028) 8.1.2 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Type (2017-2028) 8.2 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Application 8.2.1 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2017-2028) 8.2.2 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Application (2017-2028) 8.3 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Region 8.3.1 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Region (2017-2028) 8.3.2 Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Region (2017-2028) 8.3.3 China 8.3.4 Japan 8.3.5 South Korea 8.3.6 India 8.3.7 Australia 8.3.8 Taiwan 8.3.9 Indonesia 8.3.10 Thailand 8.3.11 Malaysia 8.3.12 Philippines 9 Latin America 9.1 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Type 9.1.1 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2017-2028) 9.1.2 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Type (2017-2028) 9.2 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Application 9.2.1 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2017-2028) 9.2.2 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Application (2017-2028) 9.3 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Country 9.3.1 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2017-2028) 9.3.2 Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2017-2028) 9.3.3 Mexico 9.3.4 Brazil 9.3.5 Argentina 10 Middle East and Africa 10.1 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Type 10.1.1 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2017-2028) 10.1.2 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Type (2017-2028) 10.2 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Application 10.2.1 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2017-2028) 10.2.2 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Application (2017-2028) 10.3 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size by Country 10.3.1 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2017-2028) 10.3.2 Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2017-2028) 10.3.3 Turkey 10.3.4 Saudi Arabia 11 Company Profiles 11.1 Vakzine Projekt Management (VPM) 11.1.1 Vakzine Projekt Management (VPM) Corporation Information 11.1.2 Vakzine Projekt Management (VPM) Overview 11.1.3 Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales, Price, Revenue and Gross Margin (2017-2022) 11.1.4 Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Product Model Numbers, Pictures, Descriptions and Specifications 11.1.5 Vakzine Projekt Management (VPM) Recent Developments 11.2 Serum Institute of India 11.2.1 Serum Institute of India Corporation Information 11.2.2 Serum Institute of India Overview 11.2.3 Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales, Price, Revenue and Gross Margin (2017-2022) 11.2.4 Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Product Model Numbers, Pictures, Descriptions and Specifications 11.2.5 Serum Institute of India Recent Developments 12 Industry Chain and Sales Channels Analysis 12.1 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Industry Chain Analysis 12.2 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Key Raw Materials 12.2.1 Key Raw Materials 12.2.2 Raw Materials Key Suppliers 12.3 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Production Mode & Process 12.4 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales and Marketing 12.4.1 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Channels 12.4.2 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Distributors 12.5 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Customers 13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis 13.1 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Industry Trends 13.2 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Drivers 13.3 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Challenges 13.4 VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Restraints 14 Key Findings in The Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Study 15 Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source 15.2 Author Details 15.3 Disclaimer

List of Tables Table 1. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million) Table 2. Major Manufacturers of 0.5ml Package Table 3. Major Manufacturers of 1ml Package Table 4. Major Manufacturers of 2ml Package Table 5. Major Manufacturers of Other Table 6. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million) Table 7. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million) Table 8. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Region (2017-2022) & (K Doses) Table 9. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Region (2017-2022) Table 10. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Region (2023-2028) & (K Doses) Table 11. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Region (2023-2028) Table 12. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Region (2017-2022) & (US$ Million) Table 13. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Region (2017-2022) Table 14. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Region (2023-2028) & (US$ Million) Table 15. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Region (2023-2028) Table 16. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Manufacturers (2017-2022) & (K Doses) Table 17. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Share by Manufacturers (2017-2022) Table 18. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Manufacturers (2017-2022) & (US$ Million) Table 19. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Share by Manufacturers (2017-2022) Table 20. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Price by Manufacturers (2017-2022) &(USD/Dose) Table 21. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Manufacturers Market Concentration Ratio (CR5 and HHI) Table 22. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 as of 2021) Table 23. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Manufacturing Base Distribution and Headquarters Table 24. Manufacturers VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Product Offered Table 25. Date of Manufacturers Enter into VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Table 26. Mergers & Acquisitions, Expansion Plans Table 27. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2017-2022) & (K Doses) Table 28. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2023-2028) & (K Doses) Table 29. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Share by Type (2017-2022) Table 30. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Share by Type (2023-2028) Table 31. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Type (2017-2022) & (US$ Million) Table 32. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Type (2023-2028) & (US$ Million) Table 33. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Share by Type (2017-2022) Table 34. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Share by Type (2023-2028) Table 35. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Price by Type (2017-2022) & (USD/Dose) Table 36. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Price Forecast by Type (2023-2028) & (USD/Dose) Table 37. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2017-2022) & (K Doses) Table 38. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2023-2028) & (K Doses) Table 39. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Share by Application (2017-2022) Table 40. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Share by Application (2023-2028) Table 41. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Application (2017-2022) & (US$ Million) Table 42. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Application (2023-2028) & (US$ Million) Table 43. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Share by Application (2017-2022) Table 44. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Share by Application (2023-2028) Table 45. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Price by Application (2017-2022) & (USD/Dose) Table 46. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Price Forecast by Application (2023-2028) & (USD/Dose) Table 47. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2017-2022) & (K Doses) Table 48. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2023-2028) & (K Doses) Table 49. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Type (2017-2022) & (US$ Million) Table 50. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Type (2023-2028) & (US$ Million) Table 51. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2017-2022) & (K Doses) Table 52. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2023-2028) & (K Doses) Table 53. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Application (2017-2022) & (US$ Million) Table 54. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Application (2023-2028) & (US$ Million) Table 55. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2017-2022) & (K Doses) Table 56. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2023-2028) & (K Doses) Table 57. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2017-2022) & (US$ Million) Table 58. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2023-2028) & (US$ Million) Table 59. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2017-2022) & (K Doses) Table 60. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2023-2028) & (K Doses) Table 61. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Type (2017-2022) & (US$ Million) Table 62. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Type (2023-2028) & (US$ Million) Table 63. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2017-2022) & (K Doses) Table 64. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2023-2028) & (K Doses) Table 65. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Application (2017-2022) & (US$ Million) Table 66. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Application (2023-2028) & (US$ Million) Table 67. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2017-2022) & (K Doses) Table 68. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2023-2028) & (K Doses) Table 69. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2017-2022) & (US$ Million) Table 70. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2023-2028) & (US$ Million) Table 71. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2017-2022) & (K Doses) Table 72. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2023-2028) & (K Doses) Table 73. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Type (2017-2022) & (US$ Million) Table 74. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Type (2023-2028) & (US$ Million) Table 75. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2017-2022) & (K Doses) Table 76. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2023-2028) & (K Doses) Table 77. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Application (2017-2022) & (US$ Million) Table 78. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Application (2023-2028) & (US$ Million) Table 79. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Region (2017-2022) & (K Doses) Table 80. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Region (2023-2028) & (K Doses) Table 81. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Region (2017-2022) & (US$ Million) Table 82. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Region (2023-2028) & (US$ Million) Table 83. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2017-2022) & (K Doses) Table 84. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2023-2028) & (K Doses) Table 85. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Type (2017-2022) & (US$ Million) Table 86. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Type (2023-2028) & (US$ Million) Table 87. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2017-2022) & (K Doses) Table 88. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2023-2028) & (K Doses) Table 89. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Application (2017-2022) & (US$ Million) Table 90. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Application (2023-2028) & (US$ Million) Table 91. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2017-2022) & (K Doses) Table 92. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2023-2028) & (K Doses) Table 93. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2017-2022) & (US$ Million) Table 94. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2023-2028) & (US$ Million) Table 95. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2017-2022) & (K Doses) Table 96. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Type (2023-2028) & (K Doses) Table 97. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Type (2017-2022) & (US$ Million) Table 98. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Type (2023-2028) & (US$ Million) Table 99. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2017-2022) & (K Doses) Table 100. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Application (2023-2028) & (K Doses) Table 101. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Application (2017-2022) & (US$ Million) Table 102. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Application (2023-2028) & (US$ Million) Table 103. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2017-2022) & (K Doses) Table 104. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales by Country (2023-2028) & (K Doses) Table 105. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2017-2022) & (US$ Million) Table 106. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue by Country (2023-2028) & (US$ Million) Table 107. Vakzine Projekt Management (VPM) Corporation Information Table 108. Vakzine Projekt Management (VPM) Description and Major Businesses Table 109. Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 110. Vakzine Projekt Management (VPM) VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Product Model Numbers, Pictures, Descriptions and Specifications Table 111. Vakzine Projekt Management (VPM) Recent Developments Table 112. Serum Institute of India Corporation Information Table 113. Serum Institute of India Description and Major Businesses Table 114. Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022) Table 115. Serum Institute of India VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Product Model Numbers, Pictures, Descriptions and Specifications Table 116. Serum Institute of India Recent Developments Table 117. Key Raw Materials Lists Table 118. Raw Materials Key Suppliers Lists Table 119. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Distributors List Table 120. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Customers List Table 121. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Trends Table 122. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Drivers Table 123. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Challenges Table 124. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Restraints Table 125. Research Programs/Design for This Report Table 126. Key Data Information from Secondary Sources Table 127. Key Data Information from Primary Sources List of Figures Figure 1. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Product Picture Figure 3. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Share by Type in 2021 & 2028 Figure 3. 0.5ml Package Product Picture Figure 4. 1ml Package Product Picture Figure 5. 2ml Package Product Picture Figure 6. Other Product Picture Figure 7. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Share by Application in 2021 & 2028 Figure 8. 0-5 Years Old Figure 9. 5-18 Years Old Figure 10. 18-45 Years Old Figure 11. 45-65 Years Old Figure 12. ≥65 Years Old Figure 13. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Report Years Considered Figure 14. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales 2017-2028 (K Doses) Figure 15. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue, (US$ Million), 2017 VS 2021 VS 2028 Figure 16. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue 2017-2028 (US$ Million) Figure 17. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Region in Percentage: 2021 Versus 2028 Figure 18. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Region (2017-2022) Figure 19. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Region (2023-2028) Figure 20. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales YoY (2017-2028) & (K Doses) Figure 21. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue YoY (2017-2028) & (US$ Million) Figure 22. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales YoY (2017-2028) & (K Doses) Figure 23. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue YoY (2017-2028) & (US$ Million) Figure 24. Asia-Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales YoY (2017-2028) & (K Doses) Figure 25. Asia-Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue YoY (2017-2028) & (US$ Million) Figure 26. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales YoY (2017-2028) & (K Doses) Figure 27. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue YoY (2017-2028) & (US$ Million) Figure 28. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales YoY (2017-2028) & (K Doses) Figure 29. Middle East & Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue YoY (2017-2028) & (US$ Million) Figure 30. The VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021 Figure 31. The Top 5 and 10 Largest Manufacturers of VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 in the World: Market Share by VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue in 2021 Figure 32. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021 Figure 33. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Type (2017-2028) Figure 34. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Type (2017-2028) Figure 35. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Application (2017-2028) Figure 36. Global VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Application (2017-2028) Figure 37. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Type (2017-2028) Figure 38. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Type (2017-2028) Figure 39. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Application (2017-2028) Figure 40. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Application (2017-2028) Figure 41. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Share by Country (2017-2028) Figure 42. North America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Share by Country (2017-2028) Figure 43. U.S. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028) & (US$ Million) Figure 44. Canada VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028) & (US$ Million) Figure 45. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Type (2017-2028) Figure 46. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Type (2017-2028) Figure 47. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Application (2017-2028) Figure 48. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Application (2017-2028) Figure 49. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Share by Country (2017-2028) Figure 50. Europe VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Share by Country (2017-2028) Figure 51. Germany VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028) & (US$ Million) Figure 52. France VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028) & (US$ Million) Figure 53. U.K. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028) & (US$ Million) Figure 54. Italy VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028) & (US$ Million) Figure 55. Russia VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028) & (US$ Million) Figure 56. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Type (2017-2028) Figure 57. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Type (2017-2028) Figure 58. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Application (2017-2028) Figure 59. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Application (2017-2028) Figure 60. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Share by Region (2017-2028) Figure 61. Asia Pacific VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Share by Region (2017-2028) Figure 62. China VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028) & (US$ Million) Figure 63. Japan VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028) & (US$ Million) Figure 64. South Korea VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028) & (US$ Million) Figure 65. India VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028) & (US$ Million) Figure 66. Australia VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028) & (US$ Million) Figure 67. Taiwan VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028) & (US$ Million) Figure 68. Indonesia VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028) & (US$ Million) Figure 69. Thailand VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028) & (US$ Million) Figure 70. Malaysia VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028) & (US$ Million) Figure 71. Philippines VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028) & (US$ Million) Figure 72. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Type (2017-2028) Figure 73. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Type (2017-2028) Figure 74. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Application (2017-2028) Figure 75. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Application (2017-2028) Figure 76. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Share by Country (2017-2028) Figure 77. Latin America VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Share by Country (2017-2028) Figure 78. Mexico VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028) & (US$ Million) Figure 79. Brazil VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028) & (US$ Million) Figure 80. Argentina VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028) & (US$ Million) Figure 81. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Type (2017-2028) Figure 82. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Type (2017-2028) Figure 83. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Market Share by Application (2017-2028) Figure 84. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Market Share by Application (2017-2028) Figure 85. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Sales Share by Country (2017-2028) Figure 86. Middle East and Africa VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue Share by Country (2017-2028) Figure 87. Turkey VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028) & (US$ Million) Figure 88. Saudi Arabia VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028) & (US$ Million) Figure 89. UAE VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Revenue (2017-2028) & (US$ Million) Figure 90. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Value Chain Figure 91. VPM1002 (Tuberculosis BCG Based Vaccine) for Prevent Covid-19 Production Process Figure 92. Channels of Distribution Figure 93. Distributors Profiles Figure 94. Bottom-up and Top-down Approaches for This Report Figure 95. Data Triangulation Figure 96. Key Executives Interviewed

Vakzine Projekt Management (VPM) Serum Institute of India